Overview

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
0
Participant gender:
All
Summary
The goal of this clinical research study is to learn if decitabine (given at 3 different doses) can help to control Myelodysplastic Syndrome (MDS). The safety of these 3 treatments will also be studied.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Eisai Inc.
Treatments:
Azacitidine
Decitabine
Criteria
Inclusion Criteria:

1. MDS and 5% or more marrow blasts, or IPSS risk intermediate 1-2 or high risk; or
chronic myelomonocytic leukemia

2. Performance status 0-2 (Eastern Cooperative Oncology Group (ECOG) scale); adequate
hepatic (bilirubin < 2 mg/dl) and renal functions (creatinine <2mg/dl); New York Heart
Association (NYHA) cardiac status III-IV excluded.

3. Signed informed consent

4. No prior intensive combination chemotherapy or high-dose ara-C (>/= 1g/m2 per dose).
Prior biologic therapies, targeted therapies and single agent chemotherapy allowed.

5. Patients must have been off chemotherapy for 2 weeks prior to entering this study and
recovered from the toxic effects of that therapy, unless there is evidence of rapidly
progressive disease. Use of Hydroxyurea for patients with rapidly proliferative
disease is allowed for the first two weeks on therapy.

Exclusion Criteria:

1. Nursing and pregnant females are excluded. Patients of childbearing potential should
practice effective methods of contraception. Should a woman become pregnant or suspect
she is pregnant while participating in this study, she should inform her treating
physician immediately.

2. Patients with active and uncontrolled infections

3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, or
psychiatric illness/social situations that would limit compliance with study
requirements